Campus Biomedico of Rome Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT02365935
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Campus Bio Medico | Campus Biomedico of Rome | Campus Bio Medico of Rome

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leiomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6